Novel Research Results in BRAF-Mutated, RET-Rearranged and EGFR-Inherited Lung Cancer

Speaker: Pasi Janne

P. Janne says that next generation sequencing testing allowed identification of smaller subsets of lung cancer. He describes the obstacles in bringing effective therapies to such rare patient population and elaborates results with drugs approved in melanoma for BRAF V600E mutated metastatic NSCLC, drug approved for thyroid cancer in RET-rearranged lung cancer, as well as germline EGFR T790M and association with inherited lung cancer risk.

Discussion Points

  • Available drugs effective for rare subsets of lung cancer
  • INHERIT EGFR study: More information on a rare germline mutation